Opioid and/or Opioid-Benzodiazepine Combination

	Member	r and Medicat	ion Informatio	n (required)	
Member ID:			Member Name:		
DOB:			Weight:		
Medication Name/ Strength:			Dose:		
Di	rections for use:				
			rmation (required		
Name:		NPI:		Specialty:	
Contact Person:		Office Phone:		Office Fax:	
	FAX FORM AND RELEVA CHART NOTES and/or U				
Noi	n-Preferred Opioids:				
1)		Chart Note Page #:			
	Details of failure (including duration):				
2)	Clinical rationale of possible drug interaction or contraindication that prevents use of the pref				
				Chart Note Page #:	
sup	ort-Acting Opioids: Prior Authorization moply or 3-day for dental providers. Clinical rationale for member not receive		·	l script of the same medication for a 7-day	
•				Chart Note Page #:	
2)	Clinical rationale for exceeding Utah Medicaid Quantity Limit or MME limit of 90 MME/day:				
				Chart Note Page #:	
	ng-Acting Opioids: Prior Authorization mo erapy on a long acting opioid.	ny not be required if m	ember has filled short	acting opioid within 30 days of initiating	
1)	Clinical rationale if member is younger to	than 18:			
2)	Clinical rationale if member is pregnant	:			
				Chart Note Page #:	
3)					
				Chart Note Page #:	
4)				Chart Note Page #:	
5)				two of the following: NSAIDs, non-opioid	
ر د	analgesics, antidepressants, or anticonv	_	rieu ariu raileu at least	two of the following. NSAIDS, non-opiola	
				Chart Note Page #:	
	Details of failure (including duration): _				
	Medication used:			Chart Note Page #:	
	Details of failure (including duration):				

Page 1 of 2 Last updated 1/1/2021

UTAH DEPARTMENT OF HEALTH, PRIOR AUTHORIZATION REQUEST FORM

Op	ioid and Benzodiazepine Combination: FDA Black Box Wa	ırning				
1)	Clinical rationale and diagnosis for member receiving benzodiazepine and opioid within last 45 days:					
	Chart Note Page #:					
2)	Most recent opioid prescription information:					
	Medication Name and Strength:	Quantity/Day Supply:	Date Prescribed:			
3)	Most recent benzodiazepine prescription information:					
	Medication Name and Strength:	Quantity/Day Supply:	Date Prescribed:			
Op	ioid Use Disorder (OUD): Clinical rationale for opioid reque	est if member received Medication Assi	sted Treatment (MAT), such as			
-	poxone, within the last 45 days:					
		CI				
On	ioid Tapering Plan: Provider must discuss possible reductio	on in doce tanering and discontinuation	with member			
_		· -				
De	tails of taper plan or rationale for the lack thereof:	Cl				
		CI	iait Note rage #			
	Provider has a signed opioid treatment agreement with the member. Provider has checked the Utah's Controlled Substance Database with each prescription. Provider has discussed with the member benefits and potential harm, including combining opioids with other CNS depressants. Provider has counseled members with high-risk conditions (sleep apnea, pregnancy, mental health conditions, substance abuse disorders, or children) about the heightened risk of using opioids. Member has received naloxone education.					
Re	tial authorization: Up to three (3) months -authorization: Up to six (6) months thorization for use with MAT: Up to fourteen (14) days, no	o re-authorization				
	OVIDER CERTIFICATION ertify that the information provided on this form is true and	d accurate to the best of my knowledge				
 Pre	escriber's Signature	 Date				

Page 2 of 2 Last updated 1/1/2021